CAPR

The Week

Capricor Therap (CAPR) rallied 52.46% this week to close at $9.59, outpacing the S&P 500 by roughly 51.97 percentage points. The stock swung sharply: Monday opened at $8.03, dipped to $6.34 and settled at $6.80, then climbed for three straight sessions, hitting a weekly high of $10.61 on Thursday before easing to $9.59 on Friday. Weekly amplitude came to 53.18%, with average daily volume around 13.4m shares, well above the median level.

Key Events

The week centred on the FDA’s extended review of the deramiocel biologics licence application (BLA) for Duchenne muscular dystrophy. On Monday the company announced the PDUFA target action date had been pushed back, with a new date set for November 22, an extension of about three months. The stock whipsawed after the news, at one point jumping more than 15% intraday on Tuesday. Several law firms also filed notices for a securities class action linked to an earlier clinical data announcement and subsequent 64% share price drop, with deadlines falling in late September.

Analyst Ratings

Of the nine brokers covering CAPR, two rate it buy and seven rate it hold, with no sell or underperform ratings; the consensus rating is hold. The consensus target price is $22.75, about 137.2% above the current price. Individual targets range from a low of $2.00 to a high of $54.00, a wide spread. The stock ranks 160th among 505 companies in the biotech industry by analyst rating.

The Week Ahead

On the macro front, the US will release the Dallas Fed manufacturing activity index, S&P Global manufacturing PMI final reading, ISM manufacturing PMI, JOLTS job openings, ADP private payrolls and factory orders next week. For the company itself, the FDA review of the deramiocel BLA is now in an extended phase, so further regulatory updates and any requests for supplementary data remain the key items to watch.

In Short

CAPR’s move this week tracked closely with the FDA review extension, with the stock trading between $8.03 and $10.61 amid wide swings. The consensus target sits well above spot, but the target range is extremely dispersed and the rating distribution tilts neutral rather than uniformly upward. On valuation, the trailing P/E is negative and price-to-book is around 2.25x; the latest session’s flow data showed large-lot money leaning net seller. What matters next is the pace of FDA decisions and the progress of the class action.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.